HURA

SEC source: 0000905718-22-000393 · kintara_fm4feb152022.xml · nonDerivative · entry 1

Hoffman Robert E. · CIK 0001166288 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4625 to $0.4697 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

SEC source: 0000899243-21-047520 · doc4.xml · nonDerivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,186

SEC source: 0000899243-21-047320 · doc4.xml · nonDerivative · entry 2

Zarrabian Saiid · CIK 0001495521 · Director · Head of Strategic Partnerships

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,500

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63115 to $0.6415 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · balance_after: On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0000899243-21-047320 · doc4.xml · nonDerivative · entry 1

Zarrabian Saiid · CIK 0001495521 · Director · Head of Strategic Partnerships

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,391

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.5902 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2 · balance_after: On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

SEC source: 0000899243-21-046043 · doc4.xml · nonDerivative · entry 1

Johnson Laura L. · CIK 0001589362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

SEC source: 0000899243-21-043913 · doc4.xml · derivative · entry 1

HOFFMAN ROBERT · CIK 0001166288 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,519,170

Underlying: Common Stock · 3,519,170 shares

Expires 2031-11-08

F1 · derivative.exercise_date: The option award was made to the reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to the reporting person's continued employment, the shares subject to the option shall vest as follows: 25% of the shares subject to the option shall vest on November 8, 2022, and the remainder shall vest in equal monthly installments over the following thirty-six (36) months.

SEC source: 0000905718-21-001221 · kintara_fm4sep222021.xml · derivative · entry 1

HOFFMAN ROBERT · CIK 0001166288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-09-22

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.

SEC source: 0000905718-21-001227 · kintara_fm4sep222021.xml · derivative · entry 1

Murphy Keith · CIK 0001536583 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-09-22

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.

SEC source: 0000905718-21-001225 · kintara_fm4sep222021.xml · derivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-09-22

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.

SEC source: 0000905718-21-001223 · kintara_fm4sep222021.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2031-09-22

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.

SEC source: 0000905718-21-001219 · kintara_fm4sep222021.xml · derivative · entry 1

Johnson Laura L. · CIK 0001589362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2031-09-22

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021.

SEC source: 0000905718-21-000630 · kintara_fm4apr292021.xml · derivative · entry 3

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 938 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

F2 · derivative.expiration_date: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

SEC source: 0000905718-21-000630 · kintara_fm4apr292021.xml · nonDerivative · entry 2

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,486

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

F3 · price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

SEC source: 0000905718-21-000630 · kintara_fm4apr292021.xml · nonDerivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,548

F1 · kind: The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-21-000631 · kintara_fm4apr292021.xml · derivative · entry 4

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

F2 · derivative.expiration_date: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

SEC source: 0000905718-21-000631 · kintara_fm4apr292021.xml · nonDerivative · entry 2

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,818

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

F3 · price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

SEC source: 0000905718-21-000631 · kintara_fm4apr292021.xml · nonDerivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,068

F1 · kind: The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-21-000629 · kintara_fm4apr292021.xml · derivative · entry 3

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 325 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

F2 · derivative.expiration_date: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

SEC source: 0000905718-21-000629 · kintara_fm4apr292021.xml · nonDerivative · entry 2

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Each share of Series B Preferred Stock was mandatorily converted on April 29, 2021 pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations of Series B Preferred Stock.

F3 · price: Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00.

SEC source: 0000905718-21-000629 · kintara_fm4apr292021.xml · nonDerivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,241

F1 · kind: The shares were issued as dividends to April 29, 2021 on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-21-000652 · kintara_fm4apr292021.xml · derivative · entry 1

SEYMOUR TAMARA A · CIK 0001288232 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-04-29

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, one-third of the options vest on April 29, 2022, with the remaining options vesting in eight equal quarterly installments commencing on July 29, 2022.

SEC source: 0000905718-21-000505 · kintara_fm4mar312021.xml · nonDerivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,238

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-21-000503 · kintara_fm4mar312021.xml · nonDerivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,062

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-21-000501 · kintara_fm4mar312021.xml · nonDerivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,540

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000899243-21-000044 · doc4.xml · nonDerivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,045

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000899243-21-000042 · doc4.xml · nonDerivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,518

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000899243-21-000043 · doc4.xml · nonDerivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,230

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-20-000998 · kintara_fm4sep302020.xml · nonDerivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,496

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-20-000999 · kintara_fm4sep302020.xml · nonDerivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-20-000997 · kintara_fm4sep302020.xml · nonDerivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,028

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0000905718-20-000984 · kintara_fm4sep222020.xml · derivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientifc Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-09-22

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 22, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 22, 2021.

SEC source: 0000905718-20-000967 · kintara_fm4sep152020.xml · derivative · entry 1

HOFFMAN ROBERT · CIK 0001166288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020

SEC source: 0000905718-20-000975 · kintara_fm4sep152020.xml · derivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 606,557

Underlying: Common Stock · 606,557 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021.

SEC source: 0000905718-20-000973 · kintara_fm4sep152020.xml · derivative · entry 1

Liatos John · CIK 0001821508 · Director · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,647

Underlying: Common Stock · 506,647 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021.

SEC source: 0000905718-20-000971 · kintara_fm4sep152020.xml · derivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,437

Underlying: Common Stock · 87,437 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021.

SEC source: 0000905718-20-000963 · kintara_fm4sep152020.xml · derivative · entry 1

Murphy Keith · CIK 0001536583 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020.

SEC source: 0000905718-20-000969 · kintara_fm4sep152020.xml · derivative · entry 1

Zarrabian Saiid · CIK 0001495521 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,715,004

Underlying: Common Stock · 2,715,004 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 1/6th of the options vest on March 15, 2021, with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on April 15, 2021.

SEC source: 0000905718-20-000965 · kintara_fm4sep152020.xml · derivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020.

SEC source: 0000905718-20-000961 · kintara_fm4sep152020.xml · derivative · entry 1

Johnson Laura L. · CIK 0001589362 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020.

SEC source: 0001213900-20-023272 · ownership.xml · nonDerivative · entry 1

Liatos John · CIK 0001821508 · Director · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,750

F1 · price: Received in exchange for 125,000 shares of Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") common stock, par value $0.0001 per share, in connection with the completion of the merger (the "Merger"), on August 19, 2020 (the "Effective Date"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share.

SEC source: 0001213900-20-023271 · ownership.xml · nonDerivative · entry 1

Murphy Keith · CIK 0001536583 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,010

F1 · price: Received in exchange for 115,000 shares of Adgero Biopharmaceuticals Holdings, Inc. ("Adgero") common stock, par value $0.0001 per share, in connection with the completion of the merger (the "Merger"), on August 19, 2020 (the "Effective Date"), of Adgero Acquisition Corp., a subsidiary of the Issuer, with and into Adgero, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 9, 2020. On the Effective Date, each share of Adgero common stock was converted automatically into the right to receive 1.5740 shares of the Issuer's common stock, par value $0.001 per share.

SEC source: 0001213900-20-016317 · ownership.xml · nonDerivative · entry 1

Cranston Lynda Sarah · CIK 0001633660 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by J.G. Cranston & Associates, Inc.

Disclosed balance after: 332

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0001213900-20-016319 · ownership.xml · nonDerivative · entry 1

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,474

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0001213900-20-016315 · ownership.xml · nonDerivative · entry 1

Bell John K · CIK 0001569585 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Onbelay Capital Inc.

Disclosed balance after: 9,817

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0001213900-20-016310 · ownership.xml · nonDerivative · entry 1

TOTH ROBERT JOSEPH JR · CIK 0001585020 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,214

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0001213900-20-016299 · ownership.xml · nonDerivative · entry 1

Brown Dennis M · CIK 0001569520 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,011

F1 · kind: The shares were issued as dividends on the reporting person's shares of Series B Preferred Stock.

SEC source: 0001213900-20-016308 · ownership.xml · derivative · entry 1

HOFFMAN ROBERT · CIK 0001166288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 39,567 shares

Expires 2029-09-05

F1 · kind: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.

F2 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.

SEC source: 0001213900-20-016306 · ownership.xml · derivative · entry 1

Ferrara Napoleone · CIK 0001744779 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 39,567 shares

Expires 2029-09-05

F1 · kind: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.

F2 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.

SEC source: 0001213900-20-016317 · ownership.xml · derivative · entry 2

Cranston Lynda Sarah · CIK 0001633660 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 39,567 shares

Expires 2029-09-05

F2 · kind: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.

F3 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019.

SEC source: 0001213900-20-016319 · ownership.xml · derivative · entry 2

Praill Anthony Scott · CIK 0001332948 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,366

Underlying: Common Stock · 57,170 shares

Expires 2029-09-05

F2 · kind: On September 5, 2019, the reporting person received options to purchase 57,170 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020.

F3 · derivative.exercise_date: 1/6th of the options vested on March 5, 2020 with the remaining shares vesting in equal monthly installments over a period of 30 months which commenced on April 5, 2020.